• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受和承诺疗法与暴露和反应预防对接受 SSRI 最佳剂量的强迫症患者的初步比较:伊朗的一项随机对照试验。

A Preliminary Examination of Acceptance and Commitment Therapy Versus Exposure and Response Prevention for Patients with Obsessive-Compulsive Disorder on an Optimal Dose of SSRIs: A Randomized Controlled Trial in Iran.

机构信息

University of Kurdistan, Sanandaj, Iran.

Kurdistan University of Medical Sciences, Sanandaj, Iran.

出版信息

Behav Modif. 2022 May;46(3):553-580. doi: 10.1177/0145445520982977. Epub 2020 Dec 24.

DOI:10.1177/0145445520982977
PMID:33356487
Abstract

This study compared the effects of adding acceptance and commitment therapy (ACT) or exposure and response prevention (ERP) to adults diagnosed with obsessive compulsive disorder (OCD) already on an optimal and stable dose of selective serotonin reuptake inhibitors (SSRIs). Forty adults on SSRIs who were diagnosed with OCD participated in a randomized controlled trial in Iran of 12 individual weekly sessions of either ACT+SSRI, ERP+SSRI, or continued SSRI only. The results showed significant reductions in OCD symptom severity in ACT+SSRI and ERP+SSRI conditions at posttreatment with significantly greater reductions in both conditions compared to SSRI-only at follow-up. Additionally, psychological inflexibility and use of thought control strategies significantly decreased in the ACT+SSRI condition at posttreatment and follow-up compared to the ERP+SSRI and SSRI conditions. Both conditions led to decreases in perceived importance of stop signals. Results provide cross-cultural support for the treatment of OCD using ACT and ERP as adjuncts to SSRI and modest process of change differences between ACT and ERP. Future directions and study limitations are discussed.

摘要

这项研究比较了在接受选择性 5-羟色胺再摄取抑制剂(SSRIs)最佳和稳定剂量治疗的强迫症(OCD)成年人中添加接受与承诺疗法(ACT)或暴露与反应预防(ERP)的效果。40 名接受 SSRIs 治疗且被诊断为 OCD 的成年人参加了伊朗的一项随机对照试验,他们每周接受 12 次个体治疗,分别为 ACT+SSRI、ERP+SSRI 或仅继续接受 SSRI。结果显示,在治疗后,ACT+SSRI 和 ERP+SSRI 条件下 OCD 症状严重程度显著降低,与仅接受 SSRI 相比,在随访中这两种条件下的降低更为显著。此外,与 ERP+SSRI 和 SSRI 条件相比,在治疗后和随访中,ACT+SSRI 条件下的心理灵活性和思维控制策略的使用显著降低。两种条件都导致对停止信号重要性的感知降低。结果为使用 ACT 和 ERP 作为 SSRIs 的辅助治疗 OCD 提供了跨文化支持,并且在 ACT 和 ERP 之间存在适度的变化过程差异。讨论了未来的方向和研究限制。

相似文献

1
A Preliminary Examination of Acceptance and Commitment Therapy Versus Exposure and Response Prevention for Patients with Obsessive-Compulsive Disorder on an Optimal Dose of SSRIs: A Randomized Controlled Trial in Iran.接受和承诺疗法与暴露和反应预防对接受 SSRI 最佳剂量的强迫症患者的初步比较:伊朗的一项随机对照试验。
Behav Modif. 2022 May;46(3):553-580. doi: 10.1177/0145445520982977. Epub 2020 Dec 24.
2
Adding acceptance and commitment therapy to exposure and response prevention for obsessive-compulsive disorder: A randomized controlled trial.将接纳与承诺疗法加入到强迫症的暴露和反应预防中:一项随机对照试验。
Behav Res Ther. 2018 Sep;108:1-9. doi: 10.1016/j.brat.2018.06.005. Epub 2018 Jun 22.
3
Scoping Review of Acceptance and Commitment Therapy for Obsessive-Compulsive Disorder in Iran.伊朗强迫症接受与承诺疗法的范围综述。
J Cogn Psychother. 2024 Jul 11;38(3):211-226. doi: 10.1891/JCP-2023-0009.
4
Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.选择性 5-羟色胺再摄取抑制剂治疗强迫症的早期反应:荟萃分析。
J Clin Psychiatry. 2016 May;77(5):e605-11. doi: 10.4088/JCP.14r09758.
5
Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive Disorder.接受与承诺疗法、选择性5-羟色胺再摄取抑制剂及其联合使用对改善强迫症患者的强迫症状和经验性回避的作用
Iran J Psychiatry Behav Sci. 2015 Jun;9(2):e845. doi: 10.17795/ijpbs845. Epub 2015 Jun 1.
6
Psychological Flexibility as Shared Process of Change in Acceptance and Commitment Therapy and Exposure and Response Prevention for Obsessive-Compulsive Disorder: A Single Case Design Study.心理灵活性作为接纳与承诺疗法和暴露与反应预防治疗强迫症中共同的变化过程:一项单案例设计研究。
Behav Ther. 2021 Mar;52(2):286-297. doi: 10.1016/j.beth.2020.04.011. Epub 2020 Apr 25.
7
A randomized clinical trial: Comparison of group acceptance and commitment therapy with drug on quality of life and depression in patients with obsessive-compulsive disorder.一项随机临床试验:比较团体接纳与承诺疗法和药物治疗对强迫症患者生活质量及抑郁的影响。
J Res Med Sci. 2022 Feb 18;27:9. doi: 10.4103/jrms.jrms_449_21. eCollection 2022.
8
Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.系统评价与荟萃分析:选择性5-羟色胺再摄取抑制剂与氯米帕明在儿童强迫症中的早期治疗反应
J Am Acad Child Adolesc Psychiatry. 2016 Oct;55(10):851-859.e2. doi: 10.1016/j.jaac.2016.07.768. Epub 2016 Aug 4.
9
Different Psychological Processes in Traditional and ACT-Enhanced ERP for Obsessive-Compulsive Disorder.传统与 ACT 增强型 ERP 治疗强迫症的不同心理过程。
J Cogn Psychother. 2023 Jul 1;37(3):239-251. doi: 10.1891/JCP-2021-0004.
10
[Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].[表现出不同药理反应的强迫症患者的临床特征]
Seishin Shinkeigaku Zasshi. 2006;108(12):1282-92.

引用本文的文献

1
The effectiveness of exposure and response prevention combined with pharmacotherapy for obsessive-compulsive disorder: A systematic review and meta-analysis.暴露与反应预防联合药物治疗对强迫症的有效性:一项系统评价与荟萃分析。
Front Psychiatry. 2022 Sep 15;13:973838. doi: 10.3389/fpsyt.2022.973838. eCollection 2022.
2
The Influence of Self-Esteem and Psychological Flexibility on Medical College Students' Mental Health: A Cross-Sectional Study.自尊与心理灵活性对医科大学生心理健康的影响:一项横断面研究。
Front Psychiatry. 2022 May 16;13:836956. doi: 10.3389/fpsyt.2022.836956. eCollection 2022.
3
The Applicability of Acceptance and Commitment Therapy for Obsessive-Compulsive Disorder: A Systematic Review and Meta-Analysis.
接纳与承诺疗法对强迫症的适用性:一项系统评价与荟萃分析
Brain Sci. 2022 May 17;12(5):656. doi: 10.3390/brainsci12050656.